Myriad Genetics Reports Second Quarter Fiscal Year 2012
Results
Raises Guidance for Fiscal Year 2012 on Record Second Quarter
Results
SALT LAKE CITY, Jan. 31, 2012 (GLOBE NEWSWIRE) -- Myriad
Genetics, Inc. (Nasdaq:MYGN) today announced results for its
second fiscal quarter and six months ending December 31,
2011. Revenue for the second fiscal quarter was $122.8
million, an increase of 22 percent over the $100.4 million
reported in the second fiscal quarter of 2011. Earnings per
diluted share were
$0.33, an increase of 27 percent over the same period of the
prior year.
"These results represent the second quarter in a row of
20 percent or greater year-over-year revenue growth,"
said Peter D. Meldrum, President and Chief Executive Officer
of Myriad Genetics, Inc. "As a result, I'm pleased
to announce increased guidance for fiscal 2012. We remain
focused on delivering strong top-line growth and implementing
our broader strategic plan to diversify revenue across
multiple disease indications and geographies."
Analysis of Second Fiscal Quarter 2012